Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
WuXi Clinical is expanding therapeutically - investing ‘heavily’ in oncology, CNS, GI - and plans to continue growing geographically as well, with a mission to bridge the gap between China and the rest of the world.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
WuXi LabNetwork enters an agreement with Science Exchange enabling users to order compounds directly following an increased demand for specialty chemicals.
WuXi AppTec has adopted Elsevier’s technology as the company begins to focus less on point solutions, and more on provider partnerships, says VP of procurement.
With WuXi pushing full steam ahead in its bid to go private, one expert says that the company may be envious of a competing CRO -- Hangzhou Tigermed, which is smaller than WuXi but valued at a higher price on the Shenzhen stock exchange.
WuXi PharmaTech subsidiary WuXi Biologics has begun construction on a new $150m biologics manufacturing facility in Wuxi, China, which is expected to be the largest mammalian cell culture manufacturing sire using disposable bioreactors in the world.
Competition in the notoriously tight-lipped CRO (contract research organization) and CMO (contract manufacturing organization) industries is getting fiercer as outsourcing picks up, though that hasn’t stopped one Chinese company from revealing who it...
Chinese service provider WuXi PharmaTech has sold a 5.55% stake in its wholly owned CMO (contract manufacturing organization) subsidiary SynTheAll Pharmaceutical (STA) to members of STA’s and WuXi’s management for $28m.
China-based CDMO WuXi PharmaTech unveiled Thursday that it will soon begin construction on its third cell therapy manufacturing facility -- a 145,000-square-foot cGMP facility in Philadelphia.
With biologics declared as its main driver over the next few years, CDMO Wuxi is seeing rapid manufacturing growth and planning two new facilities in the next two years.
China-based WuXi PharmaTech has acquired CRO XenoBiotic Laboratories (XBL) to bolster its bioanalytical and DMPK (Drug Metabolism and Pharmacokinetics)/ADME (absorption, distribution, metabolism, and excretion) services. Financial terms were not disclosed....
With almost 20% year-over-year growth in its manufacturing services, Chinese CRO and CMO WuXi now expects its small molecule manufacturing and biologics to be the key drivers of growth for the next several years, Ge Li, chairman and CEO of WuXi, said.
As WuXi talks of a surge in its outsourced manufacturing services, the company has begun offering high-potency active pharmaceutical ingredients (HPAPIs).
WuXi PharmaTech is partnering with Pacific Biomarkers to gain access to its menu of validated biomarker assays to support WuXi's integrated clinical trial testing services.
WuXi PharmaTech has revealed that demand for its manufacturing services increased significantly last year and forecast that its "open access" approach will help it sustain growth into 2014.
Demand for drug discovery, development services and active pharmaceutical ingredients (APIs) were the main growth drivers in Q3 according to Wuxi Pharmatech.
WuXi PharmaTech posted an operating profit of $52m (€38m) in 2009 and is optimistic about 2010, when it will make investments in laboratory services and large-scale manufacturing to drive growth in coming years.
WuXi PharmaTech’s operating income increased by 35 per cent in the third quarter, underpinned by strong growth in China-based laboratory services, but its manufacturing operations continue to struggle.
Wuxi PharmaTech’s China-based laboratory services grew by 23 per cent in Q2, outstripping expectations and resulting in the company revising its guidance for the business segment.
WuXi PharmaTech’s operating income fell by 25 per cent in Q1, in part because of an 81 per cent drop in revenues from manufacturing, but the company reconfirmed its 2009 financial guidance.
Chinese contract research provider WuXi PharmaTech slipped to a fourth quarter loss in 2008, despite reporting a strapping 74 per cent increase in sales.
China’s WuXi PharmaTech has reported a below par set of unaudited third quarter results and has cut its full-year expectations blaming the current economic climate’s impact on R&D spending within the sector.
China's Wuxi PharmaTech saw revenues race away across its divisions
in the first quarter of 2008, benefitting from the continued shift
towards outsourcing of manufacturing and laboratory functions by
the pharmaceutical industry.
